prosper: enzalutamide vs. placebo for nmcrpc
Published 5 years ago • 131 plays • Length 2:50Download video MP4
Download video MP3
Similar videos
-
3:19
live long and prosper: enzalutamide for nmcrpc
-
1:31
spartan vs. prosper: apalutamide or enzalutamide for nmcrpc?
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
0:53
embark: subset analysis of enzalutamide versus leuprolide in prostate cancer
-
3:09
nmcrpc at asco gu: aramis & prosper
-
1:55
awaiting key results for enzalutamide and apalutamide in nmcrpc
-
1:08
research highlights in nmcrpc: prosper and spartan studies
-
2:07
impact of prior therapy on enzalutamide in nmcrpc: post-hoc analysis of prosper
-
3:43
arches trial: androgen deprivation therapy with enzalutamide or placebo in mhspc
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
21:25
an update on the prosper trial: focusing on nonmetastatic crpc
-
1:18:00
urowebinar: identification and management of patients with nmcrpc
-
2:14
salv-enza: srt plus enzalutamide for psa recurrent high-risk prostate cancer delays psa progression
-
0:42
enzalutamide in the non-metastatic setting for crpc
-
21:27
focus on non-metastatic castration resistant prostate cancer
-
2:04
dr. beer on the design and results of the prevail trial
-
1:09
considerations for apalutamide versus enzalutamide in prostate cancer treatment
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer